Meeting
2015 ASCO Annual Meeting
Use of neoadjuvant chemotherapy in advanced ovarian cancer.
Authors
Larissa Meyer
The University of Texas MD Anderson Cancer Center, Houston, TX
Larissa Meyer , Angel Cronin , Charlotte C. Sun , Michael A. Bookman , Robert Allen Burger , Mihaela C. Cristea , Jennifer J. Griggs , Charles F. Levenback , Gina Mantia-Smaldone , Ursula Matulonis , Joyce C. Niland , David M. O'Malley , Alexi A. Wright
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 5563)
DOI
10.1200/jco.2015.33.15_suppl.5563
Abstract #
5563
Poster Bd #
121
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Does aggressive surgery only benefit patients with less advanced ovarian cancer?
First Author: Shinichi Tate
Poster
2018 ASCO Annual Meeting
Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial).
First Author: Anna Fagotti
Poster
2017 ASCO Annual Meeting
TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 / AGO‐OVAR OP7).
First Author: Sven Mahner
Poster
2023 ASCO Annual Meeting
BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.
First Author: Helene Blons